Cited by 347Ovarian function and disordersReproductive Biology and FertilityReproductive Health and Technologies

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; none of the 24 sources its claims cite is checked for support yet.

A randomized double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women

Open access
Fisher, Stephanie A, Reid, Robert L, Van Vugt, Dean A, Casper, Robert F·2002·Fertility and Sterility

Abstract

Objective To evaluate the ovarian follicular dynamics of cycle modification with the aromatase inhibitor letrozole compared with clomiphene citrate in normal ovulatory women.Design Randomized double-blind controlled trial.Setting Tertiary care hospital.Patient(s) Nineteen ovulatory female volunteers, ages 18-35 years.Intervention(s) Subjects were monitored in one control cycle. Subjects then received either letrozole 2.5 mg daily or clomiphene citrate 50 mg daily on days 5-9 after menses.Main outcome measure(s) Number of mature follicles, endometrial thickness and endometrial pattern at ovulation, and follicular profiles of LH, FSH, and E(2).Result(s) The number of mature follicles at the LH surge in natural cycles was 1.0 with an exaggerated response seen for treatment both with clomiphene and letrozole. There was no difference in the endometrial thickness at midcycle during either the natural cycles or the medicated cycles. LH surges and spontaneous ovulation were documented in all natural and medicated cycles. When measured daily, follicular profiles of LH and FSH are similar between the groups in both the natural and medicated cycles. In the medicated cycles, clomiphene results in a significant increase in E(2) levels, while E(2) levels in letrozole-stimulated cycles appeared lower than in natural cycles.Conclusion(s) Transient inhibition of aromatase activity in the early follicular phase with the aromatase inhibitor letrozole results in stimulation of ovarian folliculogenesis similar to that seen with clomiphene citrate with no apparent adverse effect on endometrial thickness or pattern at midcycle.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

In a randomized double-blind pilot of normal ovulatory women, letrozole 2.5 mg/day and clomiphene citrate 50 mg/day on cycle days 5–9 both increased mature follicles at the LH surge compared with natural cycles, with comparable midcycle endometrial thickness and spontaneous ovulation. Letrozole produced lower E2 levels than clomiphene and natural cycles, but the authors conclude larger trials are needed.

Key findings

  • Sixteen participants completed both cycles. The mean (±SD) number of mature follicles (≥18 mm) at the LH surge was 2.2 (±0.67) in the clomiphene-treated group and 1.7 (±0.49) in the letrozole-treated group (P=.11); natural-cycle values were 1.0 in both groups.
  • Midcycle endometrial thickness was comparable: natural cycle 9.8 (±1.6) mm with clomiphene vs 9.9 (±2.4) mm with letrozole (P=.91); treatment cycle 10.1 (±2.2) mm vs 10.6 (±2.0) mm (P=.64). No within-group difference between natural and treated cycles.
  • Tri-laminar endometrium at midcycle was present in 100% (9/9) of letrozole natural cycles vs 56% (5/9) of clomiphene natural cycles; in treatment cycles it was 71% with letrozole (P=.46) and 44% with clomiphene (P=1.00). LH surges and spontaneous ovulation were documented in all natural and medicated cycles.
  • At the LH surge, mean (±SD) E2 was 686 (±388) pmol/L with clomiphene vs 560 (±193) pmol/L with letrozole in natural cycles, and 2,047 (±930) pmol/L vs 399 (±167) pmol/L in stimulated cycles; clomiphene significantly increased E2, while letrozole E2 appeared lower than natural cycles.

Methods

  • Randomized double-blind controlled pilot at Kingston General Hospital, October 1999–April 2000. Nineteen normal ovulatory women ages 18–35 who did not desire pregnancy were enrolled; inclusion required day 3 FSH ≤10 IU/L, normal hormonal profile, and reliable contraception.
  • Each participant was monitored through one natural cycle, then randomized to letrozole 2.5 mg/day or clomiphene citrate 50 mg/day on days 5–9 after menses. Monitoring included daily LH, FSH, and E2 and transvaginal ultrasound.
  • Primary outcome was number of mature follicles (≥18 mm) at the LH surge; additional outcomes included follicular E2/LH/FSH profiles, endometrial thickness and pattern 1 day after the LH surge, and spontaneous ovulation. Analysis used Student’s t-test and Fisher’s exact test, with P<.05 significant.

Limitations

  • The paper states that no a priori power calculation was possible because letrozole had never been administered to premenopausal women; it was a small pilot designed before a larger trial in infertility patients. The authors also state that daily blood sampling may have been too infrequent to detect brief LH/FSH increases, and that whether lower E2 in letrozole cycles affects implantation or luteal function is unknown.
  • The paper states that a larger randomized trial is required to fully assess letrozole’s impact on endometrial development.
  • Evident from the text: only 16 of 19 enrolled women completed both cycles and were analyzed, and participants were normal ovulatory volunteers rather than infertile patients, so findings may not generalize to infertility or polycystic ovary syndrome populations.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s0015-0282(02)03241-7

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

19 Own result · 15 Not checked yet · 10 Own method · 3 Own interpretation

Verify all 24 references — free account
  • It may state two separate claims as one. 13
  • Probably not a substantial claim. 13
22 of 22
  • The paper relies on this without support.

    Letrozole does not cause estrogen receptor depletion.

    “Because letrozole is more rapidly eliminated than clomiphene and does not cause estrogen receptor depletion, it is likely that letrozole may not cause the adverse endometrial effects observed with clomiphene, ultimately resulting in improved pregnancy rates.”
  • The paper relies on this without support.

    Letrozole is more rapidly eliminated than clomiphene.

    “Because letrozole is more rapidly eliminated than clomiphene and does not cause estrogen receptor depletion, it is likely that letrozole may not cause the adverse endometrial effects observed with clomiphene, ultimately resulting in improved pregnancy rates.”
  • The paper relies on this without support.

    Clomiphene citrate is the current standard oral treatment for ovulation induction.

    “The efficacy of letrozole was compared with clomiphene citrate, rather than placebo, to establish its equivalence to the current standard oral treatment for ovulation induction.”
  • The paper relies on this without support.

    Normal ovulatory women are an appropriate model for evaluating letrozole before testing it in infertile women.

    “This small pilot study was designed to evaluate the potential of letrozole as an ovulation induction agent before embarking on a larger trial involving infertility patients.”
4 of 4

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Research works printed but not linked: 1

  1. Mitwally, 2001, Aromatase inhibition decreases FSH dose needed during controlled ovarian hyperstimulation, J Soc Clin Invest, 8, 85A

Cited by

Sorted by citations

See all 347

Metadata

Authors
Fisher, S. A., Reid, R. L., Van Vugt, D. A., & Casper, R. F.
Affiliations
  • Queen's University (CA)
  • University of Toronto (CA)
Corresponding author
Reid, Robert L
Venue
Fertility and Sterility
Publisher
Elsevier BV
Published
2002-08
Volume
78
Issue
2
Pages
280-285
ISSN
0015-0282 (ISSN-L)
OpenAlex
W2029278810
Cited by
347
References
26
Citations by year
2025: 2 · 2024: 4 · 2023: 2 · 2022: 2 · 2021: 5 · 2020: 4 · 2019: 5 · 2018: 6 · 2017: 37 · 2016: 8 · 2015: 41 · 2014: 35 · 2013: 28 · 2012: 38
FWCI
8.74
Type
journal article
Language
en
Open access
Locations
  • Fertility and Sterility (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
  • Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
Keywords
clomiphene citrate, letrozole, aromatase inhibitors, ovulation induction, ovarian follicle development, endometrial thickness, luteinizing hormone surge, follicle-stimulating hormone, estradiol
MeSH terms
Letrozole, Adolescent, Adult, Clomiphene, Double-Blind Method, Estrogen Antagonists, Fertility Agents, Female, Follicle Stimulating Hormone, Humans, Middle Aged, Nitriles, Ovulation, Pilot Projects, Triazoles, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review